Théa to acquire 7 branded ophthalmic products from Akorn

Article

Théa to acquire 7 branded ophthalmic products from Akorn

Laboratoires Théa SAS ("Théa") announced last Friday that it will acquire seven branded ophthalmic products from Akron Operating Company LLC.

Among these brands is Zioptan, Akron’s leading glaucoma therapy, as well as its nearly 50-person sales force, which Théa intends to expand with the anticipated launch and growth of additional products within the US, according to a news release.

In a statement, Jean-Frédéric Chibret, Théa’s president, said the acquisition is a milestone purchase for the company.

“As a fifth-generation member of a family that has spent more than150 years dedicated to eye care, I’m always excited to extend Théa’s unique expertise and passion into new markets, he said, “where our goal is to improve patient quality of life by providing innovative offerings across a full range of therapeutic areas, including glaucoma, dry eye, allergy and inflammation.”

The following Akorn brands are included in Théa’s purchase:

  • Zioptan(tafluprost ophthalmic solution), a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • AcellFX (acellular amniotic membrane), which provides a protective environment or covering for repair to the ocular surface.
  • Betimol(timolol ophthalmic solution), indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma.
  • Cosopt (dorzolamide HCl and timolol maleate ophthalmic solution), indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to beta blockers.
  • Cosopt PF (dorzolamide HCl and timolol maleate ophthalmic solution), indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension that is insufficiently responsive to beta blockers.
  • AzaSite (azithromycin ophthalmic solution), a macrolide antibiotic indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of certain microorganisms; and
  • Akten (lidocaine HCl ophthalmic gel), a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures.


Théa expects to submit its first New Drug Application (NDA) with the FDA by this year’s first quarter for its version of the glaucoma treatment latanoprost.

By the end of the 2022 first quarter, the company plans to launch, in partnership with Similasan Corporation, a new line of branded over-the-counter evidence-based dry eye drops and eyelid hygiene products.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.